Publications List - Clinical (2009 - 2014)

MOST RECENT (2009 - 2014)

2014

  1. Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. 2014. Blood 123(9): 1353-1360 IF: 9.06
  2. Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen H, Kemp C, Larson RA, Saglio G. Safety and efficacy of switching nilotinib to 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatinib or nilotinib 300 mg twice daily. 2014. Haematologica 99(7): 1204-1211 IF: 5.94
  3. Parker WT, Phillis SR, Yeung DT, Hughes TP, Scott HS, Branford S. Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. 2014. Blood 124(1): 153-155 IF: 9.06
  4. Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, Dorlhiac Llacer PE, Schwarer AP, Mahon FX, Rea D, Branford S, Purkayastha D, Collins L, Szczudio T, Leber B. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. 2014. Blood [Epub ahead of print] IF: 9.06
  5. Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, Grigg AP, Ross DM, Hughes TP. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. 2014. Blood [Epub ahead of print] IF: 9.06
  6. Lickliter JD, Taylor K, Szer J, Grigg A, Arthur C, Hughes TP, Durrant S, Filshie R, Irving I, Seldon M, Ellacott J, Boyd AW, D’Rozario J, Rooney K, Lynch K, Bradstock K, for the Australasian Leukaemia and Lymphoma Group. An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial. 2014. Leukemia and Lymphoma [Epub ahead of print] IF: 2.3
  7. Ross DM, Hughes TP. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. 2014. British Journal of Haematology 166(1): 3-11 IF: 4.94
  8. Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes JE, Guilhot F. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase inhibitor Optimization and Selectivity (TOPS) study. 2014. International Journal of Hematology 99(5): 616-624 IF: 1.68

2013

  1. Branford S, Yeung D, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J, Hughes TP. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1 the criteria for imatinib discontinuation in patients with CML. 2013. Blood 121(9):3818-3824 IF: 9.06
  2. Hochhaus A, Saglio G, Larson RA, Kim D-W, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vesus imatinib in patients with newly diagnosed chronic myeloid leukaemia in chronic phase. 2013. Blood 121(18): 3703-8 IF: 9.06
  3. Ross D, Branford S, Seymour J, Schwarer A, Arthur C, Yeung D, Dang P, Goyne J, Slader C, Filshie R, Mills A, Melo J, White D, Grigg A, Hughes T. Safety and Efficacy of Imatinib Cessation for CML Patients With Stable Undetectable Minimal Residual Disease: Results from the TWISTER Study. 2013. Blood 122(4): 515-22 IF: 9.06
  4. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. 2013. New England Journal of Medicine 369(19):1783-1796 IF: 51.66
  5. Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. 2013. Leukemia and Lymphoma 55(7): 1451-62 IF: 2.3
  6. Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L, Hughes T, Michor F, Paul J, Drummond M, Holyoake TL. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. 2013. British Journal of Haematology 163(5): 674-676 IF: 4.94
  7. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. 2013. Blood 122(6): 872-884 IF: 9.06
  8. Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. 2013. BMC Cancer 13(1):173 IF: 3.33
  9. White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A, Hughes T, Kamel-Reid S, Kim DW, Modur V, Müller MC, Pagnano KB, Pane F, Radich J, Cross NC, Labourier E. Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. 2013. Clinical Chemistry 59(6): 938-948 IF: 7.15
  10. Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. 2013. Leukemia 27(4): 907-913 IF: 10.16
  11. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. 2013. Leukemia 27(1): 107-112 IF: 10.16
  12. Hughes TP, White DL. “Which TKI? An embarrassment of riches for CML patients…” ASH Education Book. American Society of Haematology. New Orleans 2013.1:168-175.

2012

  1. Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes, M, Granvil C, Wang Y. Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial. 2012. Haematologica 97(5): 731-738 IF: 5.94
  2. Yeung D, Hughes TP. Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. 2012. Critical Reviews in Oncogenesis 17(1): 17-30 IF: 1.8
  3. Larson RA, Yin OQP, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Dermirhan E, Hughes TP, Kantarijian, le Coutre P. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukaemia in chronic phase. 2012. European Journal of Clinical Pharmacology 68(5): 723-33 IF: 2.74
  4. Yin OQ, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N, Saglio G, Hughes TP, Hochhaus A, Kantarjian HM, Larson RA. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukaemia. 2012. Cancer Chemotherapeutics and Pharmacology 70(2): 345-50 IF: 2.8
  5. Branford S, Kim D-W, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Muller MC. Initial molecular response at 3 months may predict both responses and event-free survival at 24 months in imatinib-resistant or intolerant patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (CML-CP) treated with Nilotinib. 2012. Journal of Clinical Oncology 30:4323-4329 IF: 18.04
  6. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim D-W, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukaemia in chronic phase: 48 month follow up results of a phase II study. 2012. Leukemia 26(5): 959-962 IF: 10.16
  7. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM. Nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase: ENESTnd 3 year follow up. 2012. Leukemia 26(10): 2197-2203 IF: 10.16
  8. Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalia KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukaemia in resistance/intolerance. 2012. Leukemia 4:907-13 IF: 10.16
  9. Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Gohring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hanel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saussele S, Hochhaus A and for the SAKK and the German CML study Group. Early molecular and cytogenetic response is predictive for long term progression-free and overall survival in chronic myeloid leukaemia. 2012. Leukemia 26:2096-2102 IF: 10.16
  10. Cortes J, Goldman JM, Hughes TP. Current issues in chronic myeloid leukaemia: monitoring, resistance and functional cure. 2012. Journal of the National Comprehensive Cancer Network 10(3): 1-20 IF: 4.4

2011

  1. Kantarijian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim D-W, Shou Y, Gallagenr NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukaemia in chronic phase after imatinib resistance or intolerance: 24 month follow up results. 2011. Blood 117(4):1141-1145. IF: 9.06
  2. Cortes J, Hochhaus A, Hughes TP, Kantarjian H. Front line salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukaemia. 2011. Journal of Clinical Oncology 29:524-531 IF: 18.04
  3. Branford S, Hughes TP. Mutational analysis in chronic myeloid leukaemia: when and what to do? 2011. Current Opinion in Hematology 18:111-116 IF: 4.11
  4. Hiwase DK, Yeung DT, White DL. Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. 2011. Expert Review of Hematology 4:285-299 IF: 2.38
  5. Kantarjian HM, Hochhaus A, Saglio G, Souza CD, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24 month minimum follow up of the phase-3 randomised ENESTnd trial. 2011. Lancet Oncology 12(9):841-51 IF: 25.12
  6. Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukaemia: implications and management strategies. 2011. Cancer 118(5):1181-91 IF: 5.2

2010

  1. Branford S, Hughes TP. Practical considerations for monitoring patients with chronic myeloid leukaemia. 2010. Seminars in Hematology 47(4): 327-33. IF: 3.36
  2. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim D-W, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP. Phase III randomized open label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukaemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. 2010. Journal of Clinical Oncology 28(3):424-430. IF: 18.04
  3. Osborn M, Hughes TP. Managing imatinib resistance in chronic myeloid leukaemia. 2010. Current Opinions in Hematology 17:97-103. IF: 4.11
  4. Saglio G, Kim D-W, Issaragrisil S, Le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM the ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukaemia. 2010. New England Journal of Medicine 362:2251-2259. IF: 51.66
  5. Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda J, Foroni L, Druker B, Guilhot F, Larson RA, O’Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP. Long term prognostic significance of early molecular response to imatinib in new diagnosed chronic myeloid leukaemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). 2010. Blood 16:3758-3765. IF: 9.06

2009

  1. Apperley J, Cortes JE, Dong-Wook K, Roy L, Roboz GJ, Rosti G, Bullorsky E, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Hyeoung-Joon K, Sillaber C, Hughes TP, Erben P, Van Tornout JMA, Stone RM. Dasatinib in the treatment of chronic myeloid leukaemia in accelerated phase after imatinib failure: The Start A trial. 2009. Journal of Clinical Oncology 27: 3472-3479. IF: 18.04
  2. Hughes TP, Hochhaus A. Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy. 2009. Seminars in Hematology 46(2) Supp 3:S11-S15. IF: 3.36
  3. Hughes TP,Saglio G, Branford S, Soverini S, Kim D-W, Muller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A. Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukaemia in chronic phase. 2009. Journal of Clinical Oncology 27(25): 4204-10. IF: 18.04
  4. Hochhaus A, Muller M, Radich J, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim DW, Lipton JH, Bleickardt E, Lambert A, Hughes TP. Dasatinib-associated major molecular responses in patients with chronic myeloid leukaemia in chronic phase following imatinib failure: response dynamics and predictive value. 2009. Leukemia 23(9): 1628-33. IF: 10.16
  5. White DL, Hughes TP. Predicting the response of CML patients to tyrosine kinase inhibitor therapy. 2009. Current Hematologic Malignancy Reports 4:59-65 IF: 1.85
  6. Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann, Hughes TP, Larson RA, IRIS Investigators. Six-year follow up of patients receiving imatinib for the first-line treatment of chronic myeloid leukaemia. 2009. Leukemia 23(6): 1054-61. IF: 10.16
  7. Muller MC, Cortes JE, Kim D-W, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hocchaus A. Dasatinib treatment of chronic phase chronic myeloid leukaemia: analysis of responses according to pre-existing BCR-ABL mutations. 2009. Blood 114:24 4944-4953.IF: 9.06
  8. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger F, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes TP, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R. Chronic myeloid leukaemia. An update of concepts and management recommendations of European LeukemiaNet. 2009. Journal of Clinical Oncology 27:6041-51 IF: 18.04
  9. Drummond MW, Heaney N, Kaeda J, Nicolini FE, Clark RE, Wilson G, Shepherd P, Tighe J, McLintock L, Hughes TP, Holyoake TL. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patiens who have achieved a complete cytogenetic response. 2009. Leukemia 23(6): 1199-2001. IF 10.16
  10. Ross DM. Branford S, Melo JV, Hughes TP. Reply to ‘What do we mean by sensitivity when we talk about detecting minimal residual disease?’ by Steinbach and Debatin. 2009. Leukemia 23:819-820. IF 10.16
  11. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukaemia patients after imatinib failure – does the BCR-ABL mutation status really matter. 2009. Blood 114:5426-5435. IF: 9.06
  12. Hughes TP, Branford S. Measuring minimal residual disease in chronic myeloid leukaemia: fluorescence in-situ hybridization and polymerase chain reaction. 2009. Clinical Lymphoma & Myeloma 9:(3):266-271. IF: 1.13
  13. Kantarjian H, Pasquini R, Levy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes TP, Bleickardt E, Dejardin D, Cortes J, Shah NP. Dasatinib or high-dose imatinib for chronic phase chronic myeloid leukaemia resistant to imatinib at a dose of 400 to 800 milligrams daily: two year follow up of a randomized phase 2 study (START-R). 2009. Cancer 115(18): 4136-4147. IF: 5.2 

Get in touch
+61 8 8128 4000 info@sahmri.com
You can't miss us!
North Terrace Adelaide 5000 South Australia
Postal Address
PO BOX 11060 Adelaide 5001 South Australia
Key Partners
SAHMRI is located on the traditional lands of the Kaurna Nation.

The SAHMRI community acknowledges and respects the traditional owners, the family clans who are the Kaurna Nation from the Adelaide Plains region of South Australia. We acknowledge the clans of the Kaurna Nation and the sacred knowledge they hold for their country. We pay our respects to the Kaurna Nation, their ancestors and the descendants of these living family clans today.